Amarin to Present at Two Upcoming Investor Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, and Michael Kalb, chief financial officer of Amarin, are scheduled to participate in the following
Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021
Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Three Presentations Also Featuring Virtual Exhibit Booth, Digital Product Theater and On-Line Continuing Medical Education Programming DUBLIN, Ireland and BRIDGEWATER, N.J., Nov.
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update
Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022 Introduced New Go-to-Market Strategy in U.S. to Enhance Awareness and Drive Demand for VASCEPA® Plans for Regulatory Filings and Approvals of VASCEPA in Several Additional Countries in 2022 Company to Host
Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin’s senior management team to discuss the Company's third quarter 2021 financial results on Wednesday,
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.
Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate